NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRB

Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform

Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform a

Corbus Pharmaceuticals NASDAQ: CRBP Chief Executive Yuval Cohen outlined the company's near-term cli

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Key Insights from HNSCC KOL Event Transcript

Corbus Pharmaceuticals NASDAQ: CRBP executives and oncology specialists used an ASCO-linked discussi

Wedbush analyst Robert Driscoll maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:CRB

Data affirms Corbus strategy of targeting tumor types with elevated Nectin-4 expression and clear un

NORWOOD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP

Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform

Corbus Pharmaceuticals NASDAQ: CRBP Chief Executive Officer Yuval Cohen said investors should expect

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing

NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP

NORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP

Jefferies analyst Maury Raycroft maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and lo

Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform a

Guggenheim analyst Paul Jeng reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maint

NORWOOD, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP

Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.23) per share which missed the

NORWOOD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP

NORWOOD, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP

Guggenheim analyst Paul Jeng initiates coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Bu

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) shares are down on Tuesday as the company announc

Corbus reports FDA alignment on the CRB-701 path, as analysts flag upside tied to the head and neck

FDA feedback enables Corbus to proceed with proposed registrational study design and endpoints to su

Assenagon Asset Management S.A. increased its position in shares of Corbus Pharmaceuticals Holdings,

The mean of analysts' price targets for Corbus Pharmaceuticals (CRBP) points to a 318.3% upside in t

Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform a

Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.25) per share which beat the a

NORWOOD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CR

NORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Presents at 44th Annual J.P. Morgan Healthcare Conferen

NORWOOD, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP

Assenagon Asset Management S.A. purchased a new position in Corbus Pharmaceuticals Holdings, Inc. (N

CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical stage company focused on oncology and

RBC Capital analyst Brian Abrahams maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperfo

Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.90) per share which missed the

  Monday saw 825 companies set new 52-week lows.

  On Thursday, 1076 companies hit new 52-week lows.

  On Wednesday, 340 stocks hit new 52-week lows.